Kythera Readies NDA For Double Chin Drug ATX-101
This article was originally published in The Pink Sheet Daily
Executive Summary
The specialty pharma is preparing a new drug application for its lead product candidate, hoping the demand for drugs like wrinkle-reducing toxins will translate to the submental fat market.